Literature DB >> 1868451

Expression of the diphtheria toxin A-chain coding sequence under the control of promoters and enhancers from immunoglobulin genes as a means of directing toxicity to B-lymphoid cells.

I H Maxwell1, L M Glode, F Maxwell.   

Abstract

Previous results have shown that cells can be killed by the expression of an introduced gene encoding diphtheria toxin A-fragment (DT-A) and that killing can be targeted using tissue-specific transcriptional regulatory elements. Here, we describe expression plasmids containing the DT-A gene linked with promoters and enhancers from immunoglobulin heavy chain or kappa-light chain genes. When these plasmids were transfected into cultured cells, DT-A was expressed in B-lymphoid cells but not detectably in HeLa cells or fibroblasts. A high specificity for B-cells was confirmed by assaying for luciferase reporter gene expression from a plasmid containing an analogous combination of immunoglobulin heavy chain regulatory elements. A plasmid containing an immunoglobulin-kappa promoter and enhancer was substantially less active in expressing DT-A in a pre-B-cell line than in B-lymphoma cells, suggesting the possibility of targeting DT-A expression to mature, malignant B-cells while sparing normal B-cell progenitors. By means of viral delivery vehicles, the constructs described might be applied in gene therapy for B-cell leukemias or lymphomas.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1868451

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

Review 1.  Targeted vectors for gene therapy of cancer and retroviral infections.

Authors:  W Walther; U Stein
Journal:  Mol Biotechnol       Date:  1996-12       Impact factor: 2.695

Review 2.  Direct cell killing by suicide genes.

Authors:  L A Martin; N R Lemoine
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

3.  Positive-negative selection gene targeting with the diphtheria toxin A-chain gene in mouse embryonic stem cells.

Authors:  J W McCarrick; J R Parnes; R H Seong; D Solter; B B Knowles
Journal:  Transgenic Res       Date:  1993-07       Impact factor: 2.788

4.  Prodrugs in Cancer Chemotherapy.

Authors:  Richard J Knox; Tom A Connors
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

5.  Pharmacological and genetic modulation of Wnt-targeted Cre-Lox-mediated gene expression in colorectal cancer cells.

Authors:  Michael Bordonaro; Darina L Lazarova; Alan C Sartorelli
Journal:  Nucleic Acids Res       Date:  2004-05-11       Impact factor: 16.971

Review 6.  Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting.

Authors:  W Walther; U Stein
Journal:  J Mol Med (Berl)       Date:  1996-07       Impact factor: 4.599

Review 7.  Toxin-based therapeutic approaches.

Authors:  Assaf Shapira; Itai Benhar
Journal:  Toxins (Basel)       Date:  2010-10-28       Impact factor: 4.546

8.  Selective inhibition of hepatoma cells using diphtheria toxin A under the control of the promoter/enhancer region of the human alpha-fetoprotein gene.

Authors:  M Kunitomi; E Takayama; S Suzuki; T Yasuda; K Tsutsui; K Nagaike; S Hiroi; T Tadakuma
Journal:  Jpn J Cancer Res       Date:  2000-03

Review 9.  Modular Cre/lox system and genetic therapeutics for colorectal cancer.

Authors:  Michael Bordonaro
Journal:  J Biomed Biotechnol       Date:  2009-09-30

10.  Antitumor effect of diphtheria toxin A-chain gene-containing cationic liposomes conjugated with monoclonal antibody directed to tumor-associated antigen of bovine leukemia cells.

Authors:  S Watarai; M Onuma; Y Aida; H Kakidani; H Kodama; T Yasuda
Journal:  Jpn J Cancer Res       Date:  1998-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.